Asabys Partners, a Spanish emerging manager focused on healthcare, announced it has raised €180 million for its second fund, beating its target of €150 million.
The fund, Sabadell Asabys Health Innovation Investments II, will target biopharma, medical device and digital health companies.
Asabys did not disclose the names of LPs, but affiliate title Private Equity International reports that Fund II investors include Banco de Sabadell and the European Investment Fund.
The Barcelona-based firm began fundraising in September 2022 and held a first close on €100 million February 2023, according to PEI fundraising data. Asabys said its first fund closed on €117 million.
Fund II has already invested in five companies: deepull, Orikine Bio, Gradient Denervation Technologies, ALLOX and Augustine Therapeutics. It plans to invest in a total of 12 to 15 companies in line with its “core strategy of funding biopharma, medical device and digital health companies that develop novel solutions for unmet medical needs building on solid scientific evidence and a clear benefit for patients,” the firm said in a statement.
“The successful and oversubscribed close of our SAHII II fund allows us to continue investing in the Spanish life sciences ecosystem, while strategically broadening our focus to Europe and other global markets,” said founding and managing partner Clara Campàs.
Since its inception in 2018, Asabys has raised close to €300 million, invested in 17 companies and notched three company exits. The team is composed of 11 professionals with scientific and technical expertise as well as years experience investing in the industry.
Asabys Partners, a Spanish emerging manager focused on healthcare, announced it has raised €180 million for its second fund, beating its target of €150 million.
The fund, Sabadell Asabys Health Innovation Investments II, will target biopharma, medical device and digital health companies.
Asabys did not disclose the names of LPs, but affiliate title Private Equity International reports that Fund II investors include Banco de Sabadell and the European Investment Fund.
The Barcelona-based firm began fundraising in September 2022 and held a first close on €100 million February 2023, according to PEI fundraising data. Asabys said its first fund closed on €117 million.
Fund II has already invested in five companies: deepull, Orikine Bio, Gradient Denervation Technologies, ALLOX and Augustine Therapeutics. It plans to invest in a total of 12 to 15 companies in line with its “core strategy of funding biopharma, medical device and digital health companies that develop novel solutions for unmet medical needs building on solid scientific evidence and a clear benefit for patients,” the firm said in a statement.
“The successful and oversubscribed close of our SAHII II fund allows us to continue investing in the Spanish life sciences ecosystem, while strategically broadening our focus to Europe and other global markets,” said founding and managing partner Clara Campàs.
Since its inception in 2018, Asabys has raised close to €300 million, invested in 17 companies and notched three company exits. The team is composed of 11 professionals with scientific and technical expertise as well as years experience investing in the industry.
